Edwards Lifesciences Corp
NYSE:EW
Net Margin
Edwards Lifesciences Corp
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
40.7B USD |
77%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
217.4B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
168.1B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
135.9B USD |
11%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
133.3B USD |
13%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
107.7B USD |
13%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.8B USD |
8%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
48.4B EUR |
9%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
256.5B CNY |
33%
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
31B USD |
25%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
31.6B USD |
23%
|
Edwards Lifesciences Corp
Glance View
Nestled at the intersection of medical innovation and patient care, Edwards Lifesciences Corp. has long been a pioneer in the field of heart disease solutions. Emerging from its origins in the 1950s, the company has consistently focused on advancing heart valve technology, a critical area given the prevalence and severity of cardiovascular diseases. Their journey began with the development of the first artificial heart valve, setting a foundation of innovation that continues to propel the company forward. Today, Edwards is renowned for its leadership in transcatheter aortic valve replacement (TAVR) technology, an area that revolutionizes the treatment of aortic stenosis, a condition that narrows heart valves and impedes blood flow. This shift from open-heart surgeries to less invasive procedures, facilitated by Edwards' products, has marked a significant turning point in patient care, minimizing recovery times and enhancing patient outcomes. Financially, Edwards Lifesciences thrives on a robust business model centered around its technologically advanced heart valve systems and critical care technologies. The company operates through a direct sales force as well as strategic partnerships, ensuring their devices reach hospitals and healthcare providers globally. Their commitment to research and development ensures a steady pipeline of innovative products, which not only differentiates them in the market but also drives their profitability. Revenue streams are primarily fueled by the sales of their TAVR systems, surgical heart valves, and monitoring technologies—each designed to meet the complex and evolving needs of patients with structural heart diseases. By continually investing in cutting-edge technology and expanding their global reach, Edwards Lifesciences not only supports its bottom line but also positions itself as a leader in the transformative field of medical device innovation.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Edwards Lifesciences Corp's most recent financial statements, the company has Net Margin of 76.8%.
You don't have any saved screeners yet